Poor
Not Aligned
Patient Risk:
Moderate
Summary
Many extracted claims (e.g., low-dose efficacy/specific dosing, enteric-coated rationale/compliance, combination therapy with clopidogrel/warfarin for cardiovascular risk reduction, and recommendations based on cardiovascular history/genetics) are not supported by the provided FDA label excerpts. Only basic mechanism statements and general GI bleeding risk align with the provided labeling.
Category Scores
Accurate Statements
Aspirin is also known as acetylsalicylic acid (ASA).
11 DESCRIPTION (states: 'The antiplatelet agent aspirin (acetylsalicylic acid)')
Aspirin has antiplatelet properties due to inhibiting the enzyme cyclooxygenase (COX).
12.1 Mechanism of Action ("Aspirin inhibits platelet aggregation by irreversible inhibition of platelet cyclooxygenase")
COX is responsible for producing thromboxane A2.
12.1 Mechanism of Action ("and thus inhibits the generation of thromboxane A2")
Thromboxane A2 is a powerful inducer of platelet aggregation and vasoconstriction.
12.1 Mechanism of Action ("a powerful inducer of platelet aggregation and vasoconstriction")
Aspirin increases the risk of gastrointestinal bleeding.
5.1 Risk of Bleeding ("GI side effects... and gross GI bleeding" and provides GI bleeding event rates)
Aspirin interacts with warfarin.
7.1 Drug Interaction Study Information... ("Aspirin can displace warfarin from protein binding sites...")
Unsupported Statements
The chemical formula of aspirin is C9H8O4.
No provided label excerpt supports this exact chemical formula claim.
Low-dose aspirin (75–100 mg) is effective in preventing cardiovascular events.
Provided label excerpts do not support a 75–100 mg dose range or cardiovascular-event prevention claim for aspirin.
Low-dose aspirin (75–100 mg) minimizes gastrointestinal side effects.
No provided label excerpt supports dose-range-specific GI side-effect minimization.
Enteric-coated aspirin is an aspirin modified-release formulation developed to reduce gastrointestinal side effects.
No provided label excerpt describes enteric-coated aspirin or its design rationale as modified-release to reduce GI side effects.
Enteric-coated aspirin is developed to improve patient compliance.
No provided label excerpt supports this rationale.
Aspirin is often combined with clopidogrel to enhance its antiplatelet effects.
No provided label excerpt supports clopidogrel combination or antiplatelet-enhancement framing.
Aspirin is often combined with warfarin to enhance its antiplatelet effects.
While warfarin interaction is discussed, the claim that the combination is used to enhance antiplatelet effects is not supported by the provided label excerpts.
Aspirin combination therapy with other medications such as clopidogrel and warfarin is used to reduce the risk of cardiovascular events.
No provided label excerpt supports use of these combinations to reduce cardiovascular events.
Aspirin is recommended for patients with a history of cardiovascular disease.
The provided indication excerpt is specific to 'Aspirin and Extended-Release Dipyridamole Capsule' to reduce stroke risk in specific patients; it does not support a general recommendation for cardiovascular disease history.
Aspirin is recommended for patients at high risk of cardiovascular events.
No provided label excerpt supports this recommendation wording.
Aspirin is recommended for individuals with certain genetic predispositions.
No provided label excerpt supports genetic predisposition-based recommendations.
Aspirin interacts with clopidogrel.
No provided label excerpt supports a clopidogrel interaction claim.
Contradictions
Important Omissions
Aspirin (with extended-release dipyridamole) indication should be specific to reducing stroke risk in patients with transient ischemia of the brain or completed ischemic stroke due to thrombosis, rather than general cardiovascular-event prevention.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response includes multiple medication-use and dosing/risk-reduction claims that are not supported by the provided label excerpts; while it correctly notes aspirin-related GI bleeding risk and some mechanistic/interaction details, unsupported recommendations could mislead selection of patients/therapy.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Not Aligned
Primary Issue
Major portions of the claims are not supported by the provided FDA label excerpts (notably dosing-specific efficacy, enteric-coated design/compliance rationale, combination therapy with clopidogrel/warfarin for cardiovascular-event risk reduction, and general recommendation language based on cardiovascular history/high risk/genetics).
Suggested Improvement
Restrict claims to what the provided label excerpts support: mechanism (COX→thromboxane A2), the provided product indication (stroke risk reduction in specified TIA/completed ischemic stroke patients), the listed dosing/administration for Aspirin and Extended-Release Dipyridamole Capsules, the warning about bleeding/GI bleeding, and the interaction information explicitly described (e.g., warfarin protein binding displacement; anticoagulants/antiplatelets increase bleeding risk). Remove or re-source unsupported dose ranges, enteric-coated rationale, clopidogrel interaction/combination claims, and general cardiovascular-history/genetic recommendation statements.